Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2013

01-01-2013 | Epidemiology

Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004–2007

Authors: Allison W. Kurian, Daphne Y. Lichtensztajn, Theresa H. M. Keegan, Rita W. Leung, Sarah J. Shema, Dawn L. Hershman, Lawrence H. Kushi, Laurel A. Habel, Tatjana Kolevska, Bette J. Caan, Scarlett L. Gomez

Published in: Breast Cancer Research and Treatment | Issue 1/2013

Login to get access

Abstract

Chemotherapy regimens for early stage breast cancer have been tested by randomized clinical trials, and specified by evidence-based practice guidelines. However, little is known about the translation of trial results and guidelines to clinical practice. We extracted individual-level data on chemotherapy administration from the electronic medical records of Kaiser Permanente Northern California (KPNC), a pre-paid integrated healthcare system serving 29 % of the local population. We linked data to the California Cancer Registry, incorporating socio-demographic and tumor factors, and performed multivariable logistic regression analyses on the receipt of specific chemotherapy regimens. We identified 6,004 women diagnosed with Stage I–III breast cancer at KPNC during 2004–2007; 2,669 (44.5 %) received at least one chemotherapy infusion at KPNC within 12 months of diagnosis. Factors associated with receiving chemotherapy included <50 years of age [odds ratio (OR) 2.27, 95 % confidence interval (CI) 1.81–2.86], tumor >2 cm (OR 2.14, 95 % CI 1.75–2.61), involved lymph nodes (OR 11.3, 95 % CI 9.29–13.6), hormone receptor-negative (OR 6.94, 95 % CI 4.89–9.86), Her2/neu-positive (OR 2.71, 95 % CI 2.10–3.51), or high grade (OR 3.53, 95 % CI 2.77–4.49) tumors; comorbidities associated inversely with chemotherapy use [heart disease for anthracyclines (OR 0.24, 95 % CI 0.14–0.41), neuropathy for taxanes (OR 0.45, 95 % CI 0.22–0.89)]. Relative to high-socioeconomic status (SES) non-Hispanic Whites, we observed less anthracycline and taxane use by SES non-Hispanic Whites (OR 0.63, 95 % CI 0.49-0.82) and American Indians (OR 0.23, 95 % CI 0.06–0.93), and more anthracycline use by high-SES Asians/Pacific Islanders (OR 1.72, 95 % CI 1.02–2.90). In this equal-access healthcare system, chemotherapy use followed practice guidelines, but varied by race and socio-demographic factors. These findings may inform efforts to optimize quality in breast cancer care.
Literature
1.
De Angelis R, Tavilla A, Verdecchia A et al (2009) Breast cancer survivors in the United States: geographic variability and time trends, 2005–2015. Cancer 115:1954–1966PubMedCrossRef
2.
Early Breast Cancer Trialists’ Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681–1692CrossRef
3.
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:71–85
4.
Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930–942CrossRef
5.
Berry DA, Cirrincione C, Henderson IC et al (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658–1667PubMedCrossRef
6.
Clarke M (2006) Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists’ Collaborative Group overview. Ann Oncol 17(Suppl 10):x59–x62PubMedCrossRef
7.
Blayney DW, McNiff K, Hanauer D, Miela G, Markstrom D, Neuss M (2009) Implementation of the Quality Oncology Practice Initiative at a university comprehensive cancer center. J Clin Oncol 27:3802–3807PubMedCrossRef
8.
Carlson RW, Allred DC, Anderson BO et al (2011) Invasive breast cancer. J Natl Compr Canc Netw 9:136–222PubMed
9.
Du W, Mood D, Gadgeel S, Simon MS (2009) An educational video to increase clinical trials enrollment among breast cancer patients. Breast Cancer Res Treat 117:339–347PubMedCrossRef
10.
Kimmick GG, Peterson BL, Kornblith AB et al (2005) Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol 23:2201–2207PubMedCrossRef
11.
Simon MS, Du W, Flaherty L et al (2004) Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22:2046–2052PubMedCrossRef
12.
Winn RJ (1994) Obstacles to the accrual of patients to clinical trials in the community setting. Semin Oncol 21:112–117PubMed
13.
Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439PubMedCrossRef
14.
Sparano JA, Wang M, Martino S et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–1671PubMedCrossRef
15.
Bickell NA, McAlearney AS, Wellner J, Fei K, Franco R (2011) Understanding the challenges of adjuvant treatment measurement and reporting in breast cancer: cancer treatment measuring and reporting. Med Care (electronic publication) December 30
16.
Lodrigues W, Dumas J, Rao M, Lilley L, Rao R (2011) Compliance with the commission on cancer quality of breast cancer care measures: self-evaluation advised. Breast J 17:167–171PubMedCrossRef
17.
Wagner EH, Greene SM, Hart G et al (2005) Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr 2005:3–11CrossRef
18.
Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128PubMedCrossRef
19.
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef
20.
Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619PubMedCrossRef
21.
Quan H, Li B, Couris CM et al (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676–682PubMedCrossRef
22.
Shavers VL, Brown M, Klabunde CN et al (2004) Race/ethnicity and the intensity of medical monitoring under ‘watchful waiting’ for prostate cancer. Med Care 42:239–250PubMedCrossRef
23.
24.
25.
26.
27.
Yost K, Perkins C, Cohen R, Morris C, Wright W (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703–711PubMedCrossRef
28.
Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983PubMedCrossRef
29.
Bonadonna G, Moliterni A, Zambetti M et al (2005) 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 330:217PubMedCrossRef
30.
Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U (1977) The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer 39:2904–2915PubMedCrossRef
31.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedCrossRef
32.
Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684PubMedCrossRef
33.
Telli ML, Chang ET, Kurian AW et al (2011) Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat 127:471–478PubMedCrossRef
34.
Ma H, Wang Y, Sullivan-Halley J et al (2009) Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev 18:2214–2220PubMedCrossRef
35.
Caan B, Sternfeld B, Gunderson E, Coates A, Quesenberry C, Slattery ML (2005) Life After Cancer Epidemiology (LACE) Study: a cohort of early stage breast cancer survivors (United States). Cancer Causes Control 16:545–556PubMedCrossRef
36.
Kwan ML, Ambrosone CB, Lee MM et al (2008) The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California. Cancer Causes Control 19:1065–1076PubMedCrossRef
37.
Gnant M, Harbeck N, Thomssen C (2011) St. Gallen 2011: summary of the Consensus Discussion. Breast Care (Basel) 6:136–141CrossRef
38.
Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
39.
Carlson RW, Anderson BO, Burstein HJ et al (2007) Invasive breast cancer. J Natl Compr Canc Netw 5:246–312PubMed
40.
Olivotto IA, Bajdik CD, Ravdin PM et al (2005) Population-based validation of the prognostic model ADJUVANT! For early breast cancer. J Clin Oncol 23:2716–2725PubMedCrossRef
41.
Ravdin PM, Siminoff LA, Davis GJ et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980–991PubMed
42.
Krieger N (1992) Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 82:703–710PubMedCrossRef
43.
Gordon NP (2012). Similarity of the Adult Kaiser Permanente Membership in Northern California to the Insured and General Population in Northern California: Statistics from the 2009 California Health Interview Survey. Internal Division of Research Report, Oakland, CA, Kaiser Permanente Division of Research. http://​www.​dor.​kaiser.​org/​external/​chis_​non_​kp_​2009. Accessed May 30, 2012
44.
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef
45.
Curtis E, Quale C, Haggstrom D, Smith-Bindman R (2008) Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer 112:171–180PubMedCrossRef
46.
Li CI (2005) Racial and ethnic disparities in breast cancer stage, treatment, and survival in the United States. Ethn Dis 15(2 Suppl 2):S5–S9PubMed
47.
West DW, Satariano WA, Ragland DR, Hiatt RA (1996) Comorbidity and breast cancer survival: a comparison between black and white women. Ann Epidemiol 6:413–419PubMedCrossRef
48.
Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS (2012) Decline in the use of anthracyclines for breast cancer. J Clin Oncol 30:2232–2239PubMedCrossRef
49.
Griggs JJ, Culakova E, Sorbero ME et al (2007) Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 25:2522–2527PubMedCrossRef
50.
Griggs JJ, Culakova E, Sorbero ME et al (2007) Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol 25:277–284PubMedCrossRef
51.
Lipscomb J, Gillespie TW, Goodman M et al (2012) Black–white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US. Breast Cancer Res Treat 133:285–296PubMedCrossRef
52.
Sparano JA, Wang M, Zhao F et al (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104:406–414PubMedCrossRef
53.
Wu XC, Lund MJ, Kimmick GG et al (2012) Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 30:142–150PubMedCrossRef
54.
Delate T, Bowles EJ, Pardee R et al (2012) Validity of eight integrated healthcare delivery organizations’ administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiol Biomarkers Prev 21:673–680PubMedCrossRef
Metadata
Title
Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004–2007
Authors
Allison W. Kurian
Daphne Y. Lichtensztajn
Theresa H. M. Keegan
Rita W. Leung
Sarah J. Shema
Dawn L. Hershman
Lawrence H. Kushi
Laurel A. Habel
Tatjana Kolevska
Bette J. Caan
Scarlett L. Gomez
Publication date
01-01-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2329-5

Other articles of this Issue 1/2013

Breast Cancer Research and Treatment 1/2013 Go to the issue

Preclinical Study

Lack of expression of the proteins GMPR2 and PPARα are associated with the basal phenotype and patient outcome in breast cancer

Preclinical Study

Prospective dual role of mesenchymal stem cells in breast tumor microenvironment

Preclinical study

The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients

Review

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer

Clinical trial

SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer

Epidemiology

Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits